Mucosal microbiotas and their role in stem cell transplantation

Area of Science:

• Microbiology
• Immunology
• Hematology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for hematological disorders like leukemia.
• HSCT involves immunosuppressive and antimicrobial therapies that disrupt host-microbiota interactions, particularly at mucosal sites.

Purpose of the Study:

• To review and contextualize current knowledge on the role of mucosal microbiotas in HSCT.
• To propose mechanisms underlying microbiota alterations post-HSCT.
• To discuss the potential clinical value of bacterial markers for optimizing HSCT treatment strategies.

Main Methods:

• Literature review and synthesis of existing research on mucosal microbiotas and HSCT.
• Analysis of studies reporting changes in bacterial diversity and composition after HSCT.
• Identification of potential mechanisms linking microbiota shifts to clinical complications.

Main Results:

• HSCT is associated with decreased bacterial diversity and a shift in microbial composition, often showing a depletion of Clostridia and a predominance of Proteobacteria.
• Alterations in mucosal microbiota are linked to infectious and inflammatory complications, including graft-versus-host disease.
• Specific bacterial markers may hold potential for predicting and managing HSCT outcomes.

Conclusions:

• Mucosal microbiota play a critical role in patient recovery following HSCT.
• Understanding microbiota dynamics is essential for mitigating complications and improving HSCT efficacy.
• Targeting or monitoring the microbiota presents a promising avenue for novel therapeutic strategies in HSCT.